as of 12-09-2025 12:14pm EST
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 5.9B | IPO Year: | 2020 |
| Target Price: | $72.42 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.11 - $45.30 | Next Earning Date: | 11-12-2025 |
| Revenue: | $909,045,000 | Revenue Growth: | 74.75% |
| Revenue Growth (this year): | 68.83% | Revenue Growth (next year): | 51.27% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
See how LEGN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "LEGN Legend Biotech Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.